Gastrin-releasing peptide (GRP) receptors are present in pancreatic islets, though their regulation is unknown except for homologous desensitization. The modulation of binding of GRP to mouse pancreatic islets and INS-1 cells was studied. At 60 min (steady-state), total binding of [ 125 I-Tyr 15 ] G
In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma
β Scribed by Marty F. Bartholdi; James M. Wu; Haifeng Pu; Patricia Troncoso; Peter A. Eden; Richard I. Feldman
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- French
- Weight
- 638 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Human prostate cancer (PC) overexpresses the gastrinβreleasing peptide receptor (GRPR). Radiolabeled GRPRβtargeting analogs of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPRβoverexpressing tumors. A previous study showed GRPR
BACKGROUND. Bombesin-like peptides can function as autocrine or paracrine growth factors and stimulate the growth of some cancer cells, including human prostate cancer. Three bombesin receptor subtypes, termed gastrin-releasing peptide receptor (GRPR), neuromedin B receptor (NMBR), and bombesin rece
We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both a,-macroglobulin (a,-MR) and the 39 kDa receptorassociated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases. The levels of a,-MR mRNA expression